The MHRA has approved depemokimab as an add on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

Ultra-long-acting treatment could reshape respiratory care as EU regulators back GSK's high-stakes depemokimab ahead of 2026 ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

Nasal polyps are soft, noncancerous growths on the lining of the nose or sinuses. These growths, while painless, can cause blockages that prevent the sinuses from draining properly. This can make it ...

Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content. Nasal polyp development, treatment, and recurrence, as well ...

The digital press release with multimedia content can be accessed here: Basel, June 3, 2019 - Novartis today announced positive topline data from two phase III, multicenter studies evaluating ...

Europe’s drug regulator backed GSK Plc’s drug to treat severe asthma or a common nasal condition, in the first such recommendation globally for a medicine that is pegged to become a blockbuster.

Local immunoglobulin levels were found to be significantly higher in polyp tissue specimens, but not in the blood, of patients with nasal polyps. Nasal polyp development may be associated with ...

Please provide your email address to receive an email when new articles are posted on . The need for systemic corticosteroids fell by 88%, and the need for surgery fell by 98%. Nasal polyp and ...